

Product Data Sheet

Product Name: PTER-IN-1

Cat. No.: GC79054

Chemical Properties

Cas. No. 3114432-21-9

Formula $C_{19}H_{20}N_2O_6$ M.Wt 372.37

Solubility DMSO: 25 mg/mL (67.14 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

PTERi is a selective inhibitor of PTER with selectivity towards HDACs. PTERi increases the level of N-acetyltaurine in both lean and obese mice, and reduces food intake in obese mice. PTERi can be used in the research of obesity [1].

In Vivo, PTERi (100 mg/kg; i.p.; daily/single administration) dose-dependently increases plasma N-acetyltaurine levels, reduces food intake and body weight, decreases fat mass, enhances the weight loss efficacy of Semaglutide, and prevents body weight rebound after discontinuation of GLP-1R agonists in obese mice[1].

In Vitro, PTERi (Compound 41) (1 h) potently and selectively inhibits recombinant mouse PTER-mediated N-acetyltaurine hydrolysis, with over 250-fold selectivity over HDAC enzymes[1]. PTERi exhibits only weak inhibitory activity against HDACs 1-11 and SIRTs 1-4, and shows high selectivity for PTER[1].

References:

[1]. Jonathan Z. Long, et al. Compounds, compositions, and methods for treating metabolic disorders. WO2026015683A1. 2026-01-15.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA